
Eris Lifesciences has announced its audited consolidated financial results for the quarter and year ending March 31, 2026.
The company reported a notable increase in total income and net profit, reflecting strong financial performance.
In the quarter ending March 31, 2026, Eris Lifesciences achieved a total income of ₹758.79 crore, marking a 6.4% increase from ₹713.25 crore in the same quarter the previous year.
However, this figure represents a 6.0% decline from the ₹807.47 crore recorded in the December 2025 quarter.
The company's net profit (PAT) for the March 2026 quarter surged by 172.7% YoY to ₹279.10 crore, compared to ₹102.35 crore a year ago.
This also indicates a significant 156.5% increase from ₹108.83 crore in the December 2025 quarter.
For the financial year 2026, Eris Lifesciences reported a total income of ₹3,137.17 crore, reflecting a 7.7% increase from ₹2,912.00 crore in the previous year.
The net profit for FY26 rose by 72.8% YoY to ₹647.51 crore, up from ₹374.67 crore in FY25.
Eris Lifesciences has declared an interim dividend of ₹7.21 per fully paid-up equity share of ₹1 each for the financial year 2026-2027.
The record date for determining shareholder eligibility for the dividend is set for May 29, 2026, with payment to be made on or before June 19, 2026.
As of May 20, 2026, at 2:59 PM, Eris Lifesciences share price on NSE was trading at ₹1,450.70 up by 8.57% from the previous closing price.
Eris Lifesciences has demonstrated robust financial growth in the March 2026 quarter and FY26, with significant increases in both total income and net profit. The declaration of an interim dividend further underscores the company's commitment to rewarding its shareholders.
Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: May 20, 2026, 3:12 PM IST

Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
